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Abstract
To maintain healthy mitochondrial enzyme content and function, mitochondria possess a complex protein quality control system,
which is composed of different endogenous sets of chaperones and proteases. Heat shock protein 60 (HSP60) is one of these
mitochondrial molecular chaperones and has been proposed to play a pivotal role in the regulation of protein folding and the
prevention of protein aggregation. However, the physiological function of HSP60 in mammalian tissues is not fully understood.
Here we generated an inducible cardiac-specific HSP60 knockout mouse model, and demonstrated that HSP60 deletion in adult
mouse hearts altered mitochondrial complex activity, mitochondrial membrane potential, and ROS production, and eventually led
to dilated cardiomyopathy, heart failure, and lethality. Proteomic analysis was performed in purified control and mutant
mitochondria before mutant hearts developed obvious cardiac abnormalities, and revealed a list of mitochondrial-localized
proteins that rely on HSP60 (HSP60-dependent) for correctly folding in mitochondria. We also utilized an in vitro system to
assess the effects of HSP60 deletion on mitochondrial protein import and protein stability after import, and found that both
HSP60-dependent and HSP60-independent mitochondrial proteins could be normally imported in mutant mitochondria. However,
the former underwent degradation in mutant mitochondria after import, suggesting that the protein exhibited low stability in
mutant mitochondria. Interestingly, the degradation could be almost fully rescued by a non-specific LONP1 and proteasome
inhibitor, MG132, in mutant mitochondria. Therefore, our results demonstrated that HSP60 plays an essential role in maintaining
normal cardiac morphology and function by regulating mitochondrial protein homeostasis and mitochondrial function.
Introduction
Cardiac myocytes are enriched in mitochondria in order to
generate the large amount of ATP required to maintain
normal cardiac contractile function. This energy supply
must be tightly regulated to effectively meet the demands of
the heart, especially during periods of increased workload
or adrenergic stimulation. In addition to being the core of
energy metabolism in the cell, mitochondria also regulate
many aspects of intermediate metabolism, calcium buffer-
ing, and other cellular processes such as apoptosis [1].
Furthermore, mitochondrial dysfunction has been strongly
associated with the onset and progression of various cardiac
diseases including dilated cardiomyopathy and heart failure
[2, 3].
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Although mitochondria possess their own genome, most
mitochondrial proteins are actually encoded in the nucleus.
More than 1200 proteins exist in mitochondria, but only 13
proteins are encoded by mammalian mitochondrial DNA
[4, 5]. Nuclear-encoded mitochondrial precursor proteins
have to be maintained in a relatively unfolded state in the
cytosol for efficient transportation into the mitochondria via
the narrow pores formed by tightly gated translocons [6].
Thereafter, these proteins must be correctly folded inside
the mitochondria to avoid unwanted protein-protein inter-
actions or aggregation. Mitochondria have a dedicated
repertoire of molecular chaperones located in both the
intermembrane space (IMS) and matrix to promote efficient
mitochondrial protein folding and complex assembly. The
mitochondrial chaperonin heat shock protein 60 (HSP60)
consists of both HSP60 (the homologous GroEL Escher-
ichia coli protein) and heat shock protein 10 (HSP10, the
homologous GroES Escherichia coli protein) subunits,
which form a barrel-shaped complex to primarily facilitate
the folding of relatively small, soluble monomeric proteins
[7, 8]. Mitochondrial HSP70 (mtHSP70), HSP90, and an
HSP90 homolog Tumor Necrosis Factor Receptor-
Associated Protein-1 (TRAP-1), have also been shown to
promote protein folding in mitochondria [9–12].
The mitochondrial HSP60/HSP10 complex is composed
of two heptameric rings of the large subunit (HSP60)
stacked back to back [13, 14]. The importance of this
chaperonin complex has been highlighted in Escherichia
coli and yeast, in which loss of either HSP60 or HSP10
results in a lethal phenotype [8, 15–18]. Knockout experi-
ments also demonstrated that HSP60 is essential for survival
in Drosophila [19]. In mammals, however, the physiological
roles of HSP60 and HSP10 in vivo have not been well
studied. Deletion of HSP60 in mice leads to embryonic
lethality shortly after implantation suggesting that HSP60
may be required for cell differentiation and survival during
early embryonic development [20]. In humans, two disease-
related missense mutations in HSP60 have been associated
with a dominant form of hereditary spastic paraplegia and a
recessively inherited white matter disorder called
MitCHAP60 disease, respectively [21, 22]. In cardiac tis-
sues, it has been shown that HSP60 expression was
increased following heat stress and in end-stage heart failure
[23, 24]. Furthermore, overexpression of HSP60, HSP10 or
both in cultured rat neonatal cardiomyocytes protects car-
diac cells from apoptotic cell death induced by simulated
ischemia [25], ischemia/reoxygenation [26, 27], or doxor-
ubicin [28]. Although these studies strongly suggested that
HSP60 could play an important function in cardiomyocytes,
it remains unclear whether HSP60 is required for normal
cardiac function in vivo. In the current study, we generated
an inducible cardiac-specific HSP60 knockout mouse
(HSP60CKO) model and demonstrated that deletion of
HSP60 in adult mouse cardiomyocytes resulted in dilated
cardiomyopathy and heart failure due to abnormal mito-
chondrial protein homeostasis and function.
Materials and methods
Mice
We obtained the Hsp60 (MGI: 96242) embryonic stem cell
clone containing conditional alleles with flanked exon 3
and LacZ-Neo cassettes from the International Knockout
Mouse Consortium (EUCOMM ID: 40427). To generate
male chimeras we microinjected this construct into blas-
tocysts from C57BL/6 mice (Charles River). Male chi-
meras were then bred with female Black Swiss mice
(Charles River) to generate germline-transmitted hetero-
zygous (Hsp60flox-LacZ-Neo/+) mice (Fig. S1A). The
Hsp60flox-LacZ-Neo/+ mice were then crossed with B6.Cg-Tg
(ACTFLPe)9205Dym/J (FLPe) mice (The Jackson
Laboratory) that express a flippase recombinase gene under
the control of the human ACTB promoter [29], to remove
the LacZ-Neo cassette and obtain Hsp60 floxed hetero-
zygous (Hsp60f/+) mice (Fig. S1B). To generate inducible
cardiac-specific Hsp60 knockout mice, Hsp60f/f mice were
bred with αMHC-MerCreMer (αMHC-MCM+) transgenic
mice that express a tamoxifen-inducible Cre recombinase
protein fused to two mutant estrogen receptor ligand
binding domains [30]. αMHC-MCM+Hsp60f/+ mice were
further crossed with Hsp60f/f mice to generate αMHC-
MCM+Hsp60f/f mice. To induce cardiac-specific Hsp60
gene deletion, 7–8-week-old male αMHC-MCM+Hsp60f/f
mice were intraperitoneally injected with tamoxifen (20
mg/kg/d) for four consecutive days and considered cardiac-
specific Hsp60 knockout (HSP60CKO) mice. The littermate
αMHC-MCM-Hsp60f/f mice were also treated with tamox-
ifen using the same procedure and used as control mice.
DNA analysis
Genomic DNA was extracted from mouse tails as previously
described [31], and polymerase chain reaction (PCR) was used
to genotype the offspring using the following gene-specific
primers (from 5′ to 3′): Hsp60 (Forward, TGGGTCAA
GTACTTTTATCCCCTA; Reverse, GGGAAGGCTAAGA
CCTACT CATT), αMHC-MerCreMer (Forward, GCCATA
GGCTACGGTGTAAAAG; Reverse, TTGGTCAATAAGC
CCATCATT).
Quantitative real-time PCR analysis
Quantitative real-time PCR (qRT-PCR) analysis was per-
formed as previously described [32]. Briefly, total RNA was
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extracted from heart tissues with TRIzol reagent (Invitro-
gen) and cDNA was synthesized using TransScript One-
Step gDNA Removal and cDNA Synthesis SuperMix Kit
(Transgen Biotech). qRT-PCR was performed using
TransScript Tip Green qPCR SuperMix (Transgen Biotech)
according to the manufacturer’s instructions with each
sample run at least in duplicate. Primer sequences used for
qRT-PCR analysis can be found in Supplementary Table 1.
Relative transcript abundance was normalized to Gadph as
previously described [33].
Immunostaining
Hearts were freshly harvested, fixed in 4% paraformaldehyde
diluted in phosphate buffered saline (PBS), incubated with an
ascending series of sucrose concentrations from 5 to 20%, and
embedded in optimal cutting temperature (OCT) compound
(Sakura Finetek USA Inc., Torrance, CA, USA). Cryosec-
tions (7 μm) were prepared and immunostaining was per-
formed using cleaved caspase 3 antibody (catalog no. 9661;
Cell Signaling Technologies) as previously described [34].
Histological analysis
Hearts were freshly collected, fixed in 4% paraformalde-
hyde diluted in PBS, dehydrated by ethanol, cleared in
xylene, and embedded in paraffin wax. Serial sections (5
μm) were obtained and stained with hematoxylin and eosin
(H&E) as previously described [35]. Masson’s Trichrome
staining was performed according to the manufacturer’s
protocol (Sigma).
Mitochondria preparation
Hearts were freshly harvested, washed, minced, and
homogenized in 10 volumes (v/w) of Chapel-Perry buffer
(in mM: 50 MOPS, 100 KCl, 5 MgSO4, 1 EGTA, and 1
ATP, pH 7.4) with a Polytron homogenizer at medium
speed (5 s per time, four times). After centrifugation at
200 × g for 3 min, the supernatant was collected and
centrifuged again at 300 × g for 4 min. After that, the
supernatant was collected and centrifuged at 8000 × g for
17 min. The pellet was then resuspended and represented
the mitochondrial fraction while the supernatant was
collected as the cytoplasmic fraction.
Mitochondrial complexes activity assay
The activities of the individual mitochondrial electron
transport chain (ETC) complexes I, II, and IV were deter-
mined immediately after isolating the mitochondrial fraction
from control and HSP10CKO hearts by using ETC complex
activity microplate assay kits (complex I, catalog no.
ab109721; complex II, catalog no. ab109908; complex III,
catalog no. ab109905; complex IV, catalog no. ab109911;
Abcam). The signal was quantified using a spectro-
photometer according to the protocol provided by the
manufacturer. Complex I activity was determined by mea-
suring the oxidation of nicotinamide adenine dinucleotide
(NADH) to NAD+ represented by the simultaneous reduc-
tion of a dye leading to increased absorbance at 450 nm.
Complex II activity was measured as the reduction of ubi-
quinone to ubiquinol by a decrease in absorbance at 600
nm. Complex III activity was measured in a coupled reac-
tion with a mixture solution containing succinate (electron
donor of Complex II), oxidized cytochrome c (electron
acceptor of complex III), KCN (Complex IV inhibitor) and
rotenone (Complex I inhibitor). The rate of coupled Com-
plex II+ III reaction was measured by monitoring the
conversion of oxidized cytochrome c into the reduced form,
which can be observed as an absorbance increase at OD
550 nm. Complex IV activity was determined by following
the oxidation of reduced cytochrome c as an absorbance
decrease at 550 nm.
Measurement of mitochondrial membrane potential
and ROS production
Isolation of single cardiomyocyte from adult mouse heart
by Langendorff perfusion was performed as previously
described [36]. Briefly, hearts were perfused with col-
lagenase type II (catalog no. LS004177, Worthington) to
dissociate individual cardiomyocytes. Isolated cells were
then filtered through a 100-μm mesh nylon filter before
performing sequential sedimentation to enrich for myo-
cytes, and plated onto glass-covered dishes coated with
Laminin. To measure mitochondrial membrane potential
of individual cardiomyocytes, cells were incubated with
25 nM Tetramethylrhodamine (TMRM) (catalog no.
T668, Thermofisher Scientific) for 60 min at 37 °C,
washed, and imaged by confocal microscopy using the
light of 543 nm. To determine mitochondrial superoxide
production, cells were incubated with 2 μM MitoSOX™
red mitochondrial superoxide indicator (catalog no.
M36008, Thermofisher Scientific) for 20 min at 37 °C,
washed, and imaged at 514 nm. Data were analyzed using
Image J software.
Western blotting
Freshly isolated ventricles were homogenized in lysis buffer
(20mM Tris-HCl, 20mM NaCl, 0.1mM EDTA, 1% Triton
X-100, 0.5% sodium deoxycholate) containing a protease
and phosphatase inhibitor cocktail (catalog no. B15001;
Biotool, USA). On the other hand, mitochondria were
prepared separately as mentioned above and were
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homogenized in the same lysis buffer to have subcellular
mitochondrial fractions. Protein content was measured
using the BCA Protein Assay Kit (catalog no. 23227;
Pierce, USA) and adjusted for equal loading. Standard
procedures were used to run protein samples on SDS-PAGE
gels and subsequently transferred to PVDF membranes
(Millipore, USA). The primary antibodies utilized in this
study can be found in Supplementary Table 2.
Echocardiography
Echocardiography was performed as previously described
[37]. Briefly, mice were anesthetized with 1% isoflurane
and underwent echocardiography using the Vevo 2100
ultrasound system (VisualSonics, FUJIFILM, Canada) with
a linear transducer 32–55MHz. Percent fractional short-
ening (FS) and ejection fraction (EF) were used as indica-
tors of systolic cardiac function. Measurements of heart rate
(HR), left ventricular (LV) internal diameter at end-systole
(LVIDs) and at end-diastole (LVIDd), LV posterior wall
thickness at end-systole (LVPWs) and at end-diastole
(LVPWd), and interventricular septal wall thickness at
end-systole (IVSs) and at end-diastole (IVSd) were deter-
mined from the LV M-mode tracing.
Quantitative mitochondrial proteomics by LC-MS/
MS
Hearts were collected from control and HSP60CKO mice
6 weeks post tamoxifen injection. To minimize the variation
of protein expression between animals, mitochondrial frac-
tions isolated from three independent biological replicates
were pooled for both control and HSP60CKO samples, and
submitted for proteomic analysis (PTM Biolabs, Hangzhou,
China). One proteomic analysis per pooled sample was per-
formed. In brief, mitochondrial fractions were sonicated three
times on ice using a high intensity ultrasonic processor (Sci-
entz, China) in lysis buffer (8.0M Urea, 10mM DTT, 2mM
EDTA and 1% protease inhibitor cocktail III). Protein con-
centration was determined using the 2-D Quant kit (GE
Healthcare Bioscience, USA) according to the manufacturer’s
instruction. For digestion, the protein solution was reduced
with 10 mM DTT for 1 h at 37 °C, and alkylated with 20;mM
iodoacetamide (IAA) in the dark for 45 min at room tem-
perature. Following alkylation, protein samples were diluted
to 1M urea by adding 100mM triethylammonium bicarbonate
(TEAB). Finally, trypsin was added at 1:50 trypsin-to protein
mass ratio for the first digestion overnight and 1:100 trypsin-
to-protein mass ratio for a second 4 h digestion. Approxi-
mately 300 μg protein for each sample was digested with
trypsin for the following experiments. After trypsin digestion,
the peptides were desalted using Strata X C18 SPE columns
(Phenomenex, USA) and vacuum-dried. Peptides were
reconstituted in 0.5M TEAB and processed with the 6-plex
TMT kit (Thermofisher Scientific, USA) according to the
manufacturer’s instruction. After TMT labeling, the sample
was fractionated by high pH reverse-phase HPLC using
Agilent 300Extent C18 column (5 μm particles, 4.6mm ID,
250mm length; Agilent, USA). Peptides were dissolved in
0.1% formic acid (FA), directly loaded onto a reversed-phase
pre-column (Acclaim PepMap 100; Thermofisher Scientifc,
USA). Peptide separation was performed using a reversed-
phase analytical column (Acclaim PepMap RSLC; Thermo-
fisher Scientifc, USA). The gradient was comprised of an
increase from 6 to 22% solvent B (0.1% FA in 98% acet-
onitrile) over 26min, 22–35% in 8min, and climbing to 80%
in 3min then holding at 80% for the last 3 min, all at a con-
stant flow rate of 300nl/min on an EASY-nLC 1000 UPLC
system. The resulting peptides were analyzed by Q Exacti-
veTM Plus hybrid quadrupole-Orbitrap mass spectrometer
(Thermofisher Scientific, USA). The resulting MS/MS data
were processed using Mascot search engine (V2.3.0). Tandem
mass spectra were searched against the Swissprot Mouse
database. Trypsin/P was specified as the cleavage enzyme
allowing up to 2 missing cleavages. Mass error was set to 10
parts per million (ppm) for precursor ions and 0.02 Dalton
(Da) for fragment ions. Carbamidomethyl on Cysteine, TMT-
6plex (N-term) and TMT-6plex (K) were specified as fixed
modifications and oxidation on Methione was specified as
variable modifications. FDR was adjusted to <1% and peptide
ion score was set ≥20.
In vitro transcription and translation
Human influenza hemagglutinin (HA) tag (TACCCAT
ACGATGTTCCAGATTACGCT) was added at the C-
terminus of the cDNA encoding mouse SIRT3. The con-
structed fragment was amplified by PCR and subsequently
cloned into the vector pSP64 (Promega) at the restriction
sites SmaI and HindIII. Plasmid DNA was added to an
aliquot of the TnT® Quick Master Mix (catalog no. L2080,
Promega) and incubated in a 50 µl reaction volume for
60–90 min at 30 °C to obtain HA-tagged proteins.
Mitochondrial protein import and degradation assay
Freshly isolated mitochondria were suspended in import
buffer (250 mM sucrose, 5 mM magnesium acetate, 80 mM
potassium acetate, 10 mM sodium succinate, 1 mM dithio-
threitol, 0.1 mM ADP, 20 mM HEPES-KOH, pH 7.4).
Mitochondrial protein concentrations were then measured
using the BCA Protein Assay Kit. Subsequently, 50 μg
mitochondria were diluted in 200 μl import buffer contain-
ing 10 mM ATP, followed by addition of 4 μl HA-tagged
preproteins, and incubated at 37 °C for 25 min. Mitochon-
drial protein import was stopped by addition of valinomycin
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(2.0 μM) to dissipate mitochondrial membrane potential and
subsequent centrifugation at 12,000 × g for 5 min at 4 °C.
Mitochondrial pellets were then resuspended in 200 μl
import buffer containing MG132 (50 μM in DMSO) or
vehicle (DMSO), and incubated for 50 min. After that,
mitochondria were collected by centrifugation and resus-
pended in lysis buffer (20mM Tris-HCl, 20mM NaCl,
0.1mM EDTA, 1% Triton X-100, 0.5% sodium deox-
ycholate) containing protease and phosphatase inhibitor
cocktail (catalog no. B15001, Biotool).
Statistics
Scatter diagrams were drawn using Graphpad Prism 5.
Statistical analysis was performed using a two-tailed,
unpaired Student’s t-test or two-way ANOVA with Bon-
ferroni post-hoc test for multiple comparisons (Graphpad
Prism 5). All data represent mean ± SEM (error bars). P <
0.05 was considered statistically significant.
Results
Generation of an inducible cardiac-specific Hsp60
knockout mouse model
To understand the physiological role of HSP60 in adult
hearts, we generated an inducible cardiac-specific HSP60
knockout mouse model (Fig. S1; Fig. 1a). Seven to 8-week-
old male αMHC-MCM+Hsp60f/f mice were treated with
tamoxifen to delete Hsp60 and were used as cardiac-specific
Hsp60 knockout (HSP60CKO) mice. In the HSP60CKO
hearts, Hsp60 mRNA levels were dramatically reduced as
early as 1 week post tamoxifen injection (Fig. 1b), sug-
gesting that tamoxifen-induced gene deletion was fast and
efficient. Furthermore, HSP60 protein levels were almost
completely abolished in mutant mice 11 weeks post
tamoxifen injection (Fig. 1c, d). However, the decrease in
HSP60 protein levels was slower than that of Hsp60 mRNA
expression in HSP60CKO hearts especially at the earlier time
points post tamoxifen injection (Fig. 1d), implicating that
HSP60 protein in adult cardiomyocytes has a relatively
slow turnover rate (Fig. 1b–d). The expression of voltage-
dependent anion channel 1 (VDAC1), an outer mitochon-
drial membrane protein, used as the mitochondrial protein
loading control, was not significantly changed between
control and mutant hearts (Fig. S2A, B).
Deletion of HSP60 in adult cardiomyocytes resulted
in lethality and cardiac chamber dilation
In contrast to control animals, all HSP60CKO mice died
within 14 weeks post tamoxifen injection (Fig. 2a),
suggesting that HSP60 in adult cardiomyocytes is required
for the survival of adult mice. The hearts collected from
HSP60CKO mice 11 weeks post tamoxifen treatment when
the mice started to die were apparently enlarged (Fig. 2b).
Histological analysis also revealed dramatic ventricular
chamber dilation and ventricular wall thinning in HSP60CKO
hearts (Fig. 2b). Consistently, the ratio of ventricular weight
to body weight and the ratio of lung weight to body weight
were both significantly increased in HSP60CKO mice at this
time point (Fig. 2c). This is particularly important since an
increase in the latter has regularly been used as a clinical
indication of pulmonary edema due to heart failure [38].
Furthermore, mutant hearts displayed severe cardiac
fibrosis, as indicated by interstitial collagen deposition
(Fig. 2d, e). An increased number of apoptotic cells was
also observed in mutant hearts at this time point (Fig. 2f, g),
which was associated with increased expression of the
proapoptotic protein BAX and reduced expression of the
antiapoptotic protein BCL2 (Fig. S3A, B), indicating
the activation of mitochondrial apoptotic pathways in
mutant hearts.
HSP60CKO mice developed dilated cardiomyopathy
and heart failure
We also performed echocardiographic analysis to monitor
the changes of cardiac morphology and function. No cardiac
morphological and functional changes were observed in
HSP60CKO mice prior to 9 weeks after tamoxifen injection
(Fig. 3a–h; Fig. S4A). At 9 weeks post tamoxifen injection,
the left ventricle (LV) systolic function represented by
fractional shortening (FS) and ejection fraction (EF) was
slightly decreased in HSP60CKO mice. However, cardiac
morphology evidenced by ventricular wall thickness and
internal dimension at this time point was not significantly
altered in HSP60CKO mice (Fig. 3a–h; Fig. S4B). The mass
of mutant hearts and lungs were also not changed at 6 or
9 weeks post tamoxifen injection (Fig. S4C, D). Afterwards,
enlarged LV chamber and ventricular wall thinning were
found in HSP60CKO mice 11 and 13 weeks after tamoxifen
injection, which was consistent with the histological ana-
lysis (Fig. 2b). In addition, LV systolic function was further
deteriorated in HSP60CKO mice at these two stages, as
indicated by further reduces in FS and EF (Fig. 3g, h). All
these data demonstrated that HSP60CKO mice developed
dilated cardiomyopathy and heart failure, which eventually
resulted in the death of mutant mice. It is important to note
that treatment of male αMHC-MCM+Hsp60f/+ mice with
tamoxifen using the same protocol did not cause any leth-
ality (n= 12) and cardiac dilation (Fig. S5A-C).
We also assessed the dilated cardiomyopathy in
HSP60CKO mice by measuring mRNA levels of cardiac fetal
genes including atrial natriuretic factor (ANF), brain
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natriuretic peptide (BNP), α-myosin heavy chain (αMHC),
and β-myosin heavy chain (βMHC). A slight increase of
ANF and βMHC expression was observed in HSP60CKO
hearts 6 weeks post tamoxifen injection (Fig. S6A-D),
implicating that the change of cardiac fetal gene expression
precedes alterations in cardiac morphology and function in
HSP60CKO hearts. Thereafter, the expression of all four
cardiac fetal genes was significantly altered in HSP60CKO
hearts 9 weeks and 11 weeks post tamoxifen injection.
Furthermore, expression of collagen1α1, collagen3α1,
Tgfb, and cTgf were also significantly increased in
HSP60CKO hearts at these two stages (Fig. S6E-H).
Loss of HSP60 in cardiomyocytes altered
mitochondrial function
We next examined the effects of HSP60 deletion on mito-
chondrial functions. The enzymatic activities of all four
complexes were measured in freshly isolated mitochondria
by spectrophotometric analysis. At 6 weeks post tamoxifen
injection, no significant difference was observed in the
activities of all four complexes between control and mutant
mitochondria (Fig. 4a–d). At 9 weeks post tamoxifen
injection, the activities of complex I and complex III in
HSP60CKO mitochondria were significantly impaired,
whereas the activities of complex II and complex IV were
not significantly altered at this time point (Fig. 4a–d). Later
on, the activities of all four complexes in HSP60CKO mito-
chondria were significantly impaired 11 weeks post tamox-
ifen injection (Fig. 4a–d). We also measured mitochondrial
potential and production of mitochondrial reactive oxygen
species (ROS). Consistent with the changes in complex
activities, reduced mitochondrial potential and increased
mitochondrial ROS levels were observed in HSP60CKO
cardiomyocytes at 9 weeks post tamoxifen injection but not
at 6 weeks post tamoxifen injection (Fig. 4e, f).
Deletion of HSP60 perturbed mitochondrial protein
homeostasis
To further understand the effects of HSP60 deletion on
cardiac mitochondrial protein homeostasis, we performed
Fig. 1 Generation and characterization of inducible cardiac-specific
HSP60 knockout mouse model. a Schematic diagram of mouse
breeding strategy to generate inducible cardiac-specific HSP60
knockout mice. αMHC-MCM+Hsp60f/f mice treated with tamoxifen
were used as cardiac-specific HSP60 knockout (HSP60CKO) mice. b
The mRNA levels of Hsp60 gene in control and HSP60CKO hearts
measured by quantitative RT-PCR. n= 3–4 mice per group. c, d
Western blot analysis of HSP60 protein in the whole heart tissue and in
the mitochondrial fraction (Mito) of control and HSP60CKO hearts at
1 week (1w), 2 weeks (2w), 6 weeks (6w), and 11 weeks (6w) post
tamoxifen injection. GAPDH and VDAC1 were used as the loading
control for whole heart and mitochondrial proteins, respectively. n=
3–5 mice per group. All Data represent mean ± SEM. Significance was
determined by two-tailed, unpaired Student’s t-test. *p < 0.05, **p <
0.01 versus control. ***p < 0.001 versus control
592 F. Fan et al.
quantitative proteomic analysis in purified mitochondria
prior to the emergence of cardiac morphological and func-
tional defects in mutant mice. In total, 2194 proteins were
quantified, among which 676 proteins, accounting for about
30% of total identified proteins, were considered as the
mitochondrial-localized proteins according to the online
mitochondrial protein database including MitoCarta [5],
MitoMiner [39], and the UniProt annotation, while the other
detected proteins represented co-purifying contaminants.
These 676 mitochondrial proteins could be divided into
14 subgroups according to their functional classification
(Fig. 5a), among which 80 proteins were identified as
components of mitochondrial electron transport chain
(ETC; Table S3). When setting the quantification ratio of
>1.5 as the upregulated threshold and <0.67 as the down-
regulated threshold, 121 mitochondrial-localized proteins
were downregulated and only eight mitochondrial-localized
proteins were upregulated in HSP60CKO sample relative to
the control sample (Table S4), in which most down-
regulated proteins were involved in processes such as lipid
metabolism, amino acid metabolism, and RNA/DNA/pro-
tein synthesis (Fig. 5b). Furthermore, 10 ETC proteins were
downregulated in mutant sample, all of which belong to
ETC complex I (Table S3), implicating that complex I
components might be more susceptible to HSP60 deficiency
than the other complexes.
Individually, the ratio of HSP60 protein in mutant
mitochondria to the control is 0.278 (Fig. 5c), which is very
close to 32.4% as revealed by western blotting (Fig. 1d).
VDAC1 that was used as the mitochondrial protein loading
control was also not different between mutant and control
samples (Fig. 5c). Western blotting analysis was further
performed to validate the reliability of the proteomic data,
and revealed that protein levels of SUCLG2, LDHD, CPT2,
ALDH2, BCKDHB, SIRT3, RTN4IP1, and OXCT1 were
all significantly decreased in mutant mitochondria at
Fig. 2 Deletion of HSP60 in adult cardiomyocytes results in mouse
lethality and dilated cardiomyopathy. a Survival curves of control (n
= 12) and HSP60CKO (n= 16) mice after tamoxifen injection. Sig-
nificance was determined by the Kaplan–Meier survival analysis. p <
0.001 versus control. b Representative hearts (top) and H&E stained
sections (bottom) of control and HSP60CKO mice 11 weeks
post tamoxifen injection. c Ratios of ventricle weight to body weight
(VW/BW) and lung weight to body weight (LW/BW) in control and
HSP60CKO mice 11 weeks post tamoxifen injection. n= 6 mice per
group. d Masson’s trichrome staining of ventricular sections revealed
increased fibrosis (blue) in HSP60CKO hearts 11 weeks post tamoxifen
injection. e Ratios of fibrosis area to the total cell area. n= 4 per
group. f Immunostaining of cell apoptosis marker cleaved caspase 3
(red) in control and HSP60CKO ventricular sections 11 weeks post
tamoxifen injection. The sections were counterstained with DAPI
(blue) to visualize the nucleus. g Ratios of cleaved caspase 3-positive
nuclei to the total nuclei. n= 4 per group. All Data represent mean ±
SEM. Significance was determined by two-tailed, unpaired Student’s t-
test. **p < 0.01, ***p < 0.001 versus control
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Fig. 3 Echocardiographic assessment of cardiac morphology and
function in control and HSP60CKO mice. The analysis were performed
on left ventricular M-mode in control and HSP60CKO mice prior to
(pre), 4 weeks (4w), 6 weeks (6w), 9 weeks (9w), 11 weeks (11w), and
13 weeks (13w) post tamoxifen injection, respectively. a, b Mea-
surement of left ventricular internal diameter at end-diastole (LVIDd)
and at end-systole (LVIDs). c, d Measurement of interventricular
septal wall thickness at end-diastole (IVSd) and at end-systole (IVSs).
e, f Measurement of left ventricular posterior wall thickness at end-
diastole (LVPWd) and at end-systole (LVPWs). g, h Quantitative
analysis of left ventricular fractional shortening (FS) and ejection
fraction (EF) of control and HSP60CKO hearts. All Data represent
mean ± SEM; n= 8–12 mice per group. Significance was determined
using the two-way ANOVA analysis with Bonferroni post-hoc test. *p
< 0.05, **p < 0.01, ***p < 0.001 versus control
Fig. 4 Measurement of mitochondrial functions in control and
HSP60CKO hearts. a–dMeasurement of mitochondrial complex I (a), II
(b), III (c), and IV (d) enzymatic activities in freshly isolated mito-
chondria from control and HSP60CKO mice at 6 weeks (6w), 9 weeks
(9w) and 11 weeks (11w) post tamoxifen injection. n= 4–7 mice per
group. e Measurement of mitochondrial membrane potential in car-
diomyocytes isolated from control and HSP60CKO hearts 6 weeks and
9 weeks post tamoxifen injection. n= 5–6 mice per group. f Mea-
surement of mitochondrial ROS levels in cardiomyocytes isolated
from control and HSP60CKO hearts 6 weeks and 9 weeks post
tamoxifen injection. n= 6–7 mice per group. All Data represent mean
± SEM. Significance was determined using the two-way ANOVA
analysis with Bonferroni post-hoc test. *p < 0.05, **p < 0.01, ***p <
0.001 versus control
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6 weeks post tamoxifen injection, which was also consistent
with the proteomic analysis (Fig. 5c, d; Fig. S7A). Fur-
thermore, these eight proteins were further reduced in
mutant mitochondria 11 weeks post tamoxifen injection,
which coincided well with the change of HSP60 protein
level between these two stages (Fig. 1c). Therefore, these
data suggested our proteomic data are highly reliable, fur-
ther validating our findings about the deleterious effects of
HSP60 deletion on mitochondrial protein levels.
Loss of HSP60 altered mitochondrial protein quality
control
We further investigated the mechanisms underlying the
downregulation of mitochondrial proteins by HSP60 dele-
tion. First, mRNA levels of Suclg2, Ldhd, Cpt2, Aldh2,
Bckdhb, Sirt3, Rtn4ip1, and Oxct1 genes were not sig-
nificantly altered between control and HSP60CKO hearts at
6 weeks post tamoxifen injection (Fig. S7B), suggesting
that HSP60 deletion in cardiomyocytes did not change the
transcription profile of these genes. We next examined
whether HSP60 deletion could result in increases of
unfolded or misfolded proteins and subsequent protein
degradation. In mitochondria, an increase in unfolded or
misfolded proteins will trigger the mitochondrial unfolded
protein responses (UPRmt) to increase chaperone capacity
and re-establish homeostasis within the mitochondrial
protein-folding environment [40]. Therefore, we measured
the expression of mtHsp70 and Chop, two molecular mar-
kers of UPRmt in control and HSP60CKO hearts. However,
no significant difference in expression of mtHsp70 and
Chop was found between control and HSP60CKO hearts
6 weeks post tamoxifen injection (Fig. 6a), suggesting that
no obvious UPRmt was induced in the mutant hearts at this
time point. We also investigated the effects of HSP60
deletion on the expression of mitochondrial proteases. At
least two types of ATP-dependent proteases, Lon and
ClpXP, are localized in the mitochondrial matrix in various
organisms [41, 42]. The level of LONP1, a major member
of Lon protease family, was not significantly altered in
HSP60CKO hearts 6 weeks post tamoxifen injection (Fig. 6b,
c). In addition, the level of HTRA2, a serine protease
located in the mitochondrial intermembrane space and
released from mitochondria during apoptosis [43, 44], was
also not significantly changed in mutant hearts at this time
point (Fig. 6b, c). In contrast, the level of CLPP, a pro-
teolytic subunit of the ClpXP protease, was significantly
reduced in HSP60CKO hearts at this time point, which is
Fig. 5 Proteomic analysis and validation of mitochondrial proteins in
control and HSP60CKO hearts 6 weeks post tamoxifen injection. a Pie
chart showing functional classification of mitochondrial-localized
proteins characterized from proteomic analysis and distribution of
each functional category. b Numbers of differentially expression
proteins (DEPs) including downregulated (Down) and upregulated
(Up) proteins in each functional category. c Expression changes of
individual mitochondrial proteins in HSP60CKO hearts compared with
control hearts revealed by the proteomic analysis. d Western blot
analysis was used to validate expression changes of individual mito-
chondrial proteins in HSP60CKO hearts. Mitochondria were isolated
from control and HSP60CKO hearts at 6 weeks (6w) and 11 weeks
(11w) post tamoxifen injection, and total 10 proteins including HSP60,
SUCLG2, LDHD, CPT2, ALDH2, BCKDHB, SIRT3, RTN4IP1,
OXCT1, and VDAC1 were analyzed by western blot
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consistent with what we found by proteomic analysis
(Fig. 5c; Fig. 6b, c).
We also set up different in vitro systems to assess the
effects of HSP60 deletion on mitochondrial protein degra-
dation. Neonatal cardiomyocytes (NCMs) and cardiac
fibroblasts (NCFs) were isolated from HSP60f/f mice, cul-
tured and treated with adenovirus-Cre (Adv-Cre). Adv-Cre
treatment was able to reduce Hsp60 mRNA levels but not
protein levels in NCMs (Fig. S8), probably because HSP60
protein has a relatively long turnover time in NCMs, as is
the case in adult cardiomyocytes (Fig. 1c, d). In NCFs, Adv-
Cre treatment efficiently reduced both HSP60 mRNA and
protein levels (Fig. S9A, B). Furthermore, HSP60 deletion
also reduced expression of SIRT3 and SUCLG2 in NCFs
(Fig. S9B). More importantly, addition of MG132, an
inhibitor of the 26S proteasome also known to enter mito-
chondria where it can inhibit LONP1 [45, 46], significantly
rescued the downregulation of SIRT3 and SUCLG2 protein
in Adv-Cre-treated NCFs (Fig. S9C, D).
To further assess the contribution of cardiac mitochon-
dria to protein degradation, we isolated mitochondria from
control and HSP60CKO hearts 6 weeks post tamoxifen
injection, and performed protein import and degradation
assays using the in vitro generated HA-tagged SIRT3 and
HA-tagged NDUFA9 (Fig. 7a). NDUFA9 is a complex I
component and was examined as an HSP60-independent
protein since its expression was not significantly changed in
HSP60CKO mitochondria as revealed by both proteomics
and western blot analyses (Table S4; Fig. S10A, B). We
found that import of HA-tagged SIRT3 or HA-tagged
NDUFA9 into control and HSP60CKO mitochondria was
comparable (Fig. 7b, c; Fig. S9C), suggesting that mito-
chondrial protein import was not affected by deletion of
HSP60. In other words, downregulation of HSP60-
dependent proteins such as SIRT3 in mutant mitochondria
was not a consequence of impaired mitochondrial protein
import. Furthermore, no degradation of SIRT3 was
observed in control mitochondria 50 min after import,
whereas about 30% of imported protein had been degraded
in mutant mitochondria within the same period (Fig. 7b, c).
However, no degradation of NDUFA9 could be found
in either control or HSP60CKO mitochondria (Fig. S10C).
Interestingly, addition of MG132 almost completely
rescued SIRT3 degradation in mutant mitochondria
(Fig. 7d, e). Taken together, these data strongly suggested
that HSP60-dependent mitochondrial proteins could not be
normally folded in mutant mitochondria and thus underwent
protein degradation that mainly relied on LONP1.
Discussion
In our present study, we used an inducible cardiac-specific
αMHC-MerCreMer system to delete HSP60 in adult mouse
Fig. 6 Assessment of mitochondrial unfolded protein response
(UPRmt) and mitochondrial protease expression in control and
HSP60CKO hearts. a Mitochondrial UPRmt was assessed by quantita-
tive RT-PCR analysis of mtHsp70 and Chop mRNA levels in control
and HSP60CKO hearts at 6 weeks (6w), 9 weeks (9w) and 11 weeks
(11w) post tamoxifen injection. n= 6–7 mice per group. b, c Western
blotting (b) and quantitative analysis (c) of mitochondrial proteases
including CLPP, LONP1, and HTRA2 in control and HSP60CKO
hearts at 6 weeks, 9 weeks and 11 weeks post tamoxifen injection. n=
3–6 mice per group. All Data represent mean ± SEM. Significance was
determined using the two-way ANOVA analysis with Bonferroni post-
hoc test. *p < 0.05, ***p < 0.001 versus control
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cardiomyocytes. We found that deletion of HSP60 led to
cardiac chamber dilation and left ventricular dysfunction,
accompanied with a dramatic increase in the ratio of lung to
body weight, and premature death, demonstrating that
HSP60 deletion in adult cardiomyocytes resulted in dilated
cardiomyopathy, which further led to heart failure and leth-
ality (Fig. S11). Although knockout experiments have shown
that HSP60 is essential for the survival of Escherichia coli,
yeast, Drosophila, and mice [8, 15–20], the in vivo functions
of HSP60 in cardiac physiology and diseases have not been
well studied. Therefore, our present study provided evidence
for the first time, to our knowledge, that HSP60 plays an
essential role in maintaining normal cardiac morphology and
function in mice. On the other hand, deletion of HSP60 in
adult mouse cardiomyocytes was also associated with an
increase of cell apoptosis and cardiac fibrosis in the hearts,
which is also consistent with a previous study showing that
reduced HSP60 expression could increase cell apoptosis in
cultured neonatal cardiomyocytes [47].
The HSP60 chaperonin is located in the matrix and
consists of both HSP60 and HSP10 subunits to form a
barrel-shaped complex that has been suggested to facilitate
folding of relatively small, soluble monomeric proteins
[7, 8]. In Escherichia coli, ~250 different proteins were
found to interact with GroEL (HSP60 from Escherichia
coli), among which only about 85 proteins exhibited an
obligate dependence on GroEL for folding, suggesting that
the others can utilize either GroEL or the other chaperones
for folding [48]. In mammals, the effects of HSP60 loss on
mitochondrial protein homeostasis remain undefined.
Fig. 7 Measurement of protein import and degradation in isolated
control and HSP60CKO mitochondria. Mitochondria were isolated from
control and HSP60CKO hearts 6 weeks post tamoxifen injection. a
Schematic diagram showing the procedure of mitochondrial protein
import and degradation assay. Mitochondria were first incubated with
HA-tagged pre-protein for 25 min. Import of HA-tagged mouse
mitochondrial pre-protein and subsequent degradation was then
assessed by western blotting of mitochondrial protein lysates extracted
at 0 min and 50 min after the addition of valinomycin, respectively. b,
c Western blotting (b) and quantitative analysis (c) showing that
protein import was comparable between control and HSP60CKO
mitochondria while protein was degraded more rapidly in HSP60CKO
mitochondria. n= 6 per group. Data represent mean ± SEM. Sig-
nificance was determined using the two-way ANOVA analysis with
Bonferroni post-hoc test. **p < 0.01 versus HSP60CKO (0 min). d, e
Western blotting (d) and quantitative analysis (e) showing that MG132
could significantly impair protein degradation in HSP60CKO mito-
chondria. n= 4 per group. Data represent mean ± SEM. Significance
was determined using the two-way ANOVA analysis with Bonferroni
post-hoc test. *p < 0.05, **p < 0.01 versus HSP60CKO (50 min)
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Deletion of HSP60 in mice resulted in a very early
embryonic lethality [20], which makes it impossible to use
homozygous mutant mice for further functional and bio-
chemical studies. On the other hand, proteomic analysis of
mitochondria from heterozygous mutant mice which
express half level of HSP60 protein revealed that UQCRC1
and SOD2 were highly dependent on appropriate HSP60/
HSP10 chaperone complex function [49, 50]. In our present
study, we also performed proteomic analysis to identify
effects of HSP60 deletion on mitochondrial protein home-
ostasis. We identified 2194 proteins in total, but only 676
proteins (30.8% of total identified proteins) were char-
acterized as mitochondrial-localized proteins. This low
percentage might largely arise from co-purifying con-
taminants that has been found to represent up to 75% of
proteins detected in other MS/MS experiments [51]. Among
these 676 identified mitochondrial-localized proteins, 121
proteins were downregulated and only eight proteins were
upregulated in the HSP60CKO hearts relative to their control
counterparts. Western blot analysis of a selected subset of
proteins confirmed proteomic results. Therefore, here we
provided for the first time, at least to our knowledge, a list
of mitochondrial proteins that require HSP60-mediated
chaperone activity to maintain their protein levels in the
mitochondria of adult mouse cardiomyocytes. We also
believe it will be informative to determine which mito-
chondrial proteins bind directly to HSP60.
Most components of ETC complexes were identified in
our proteomic analysis including 38 proteins of complex I,
four proteins of complex II, nine proteins of complex III, 13
proteins of complex IV, and 16 proteins of complex V. In
HSP60 mutant mitochondria, 10 ETC components were
downregulated relative to controls, all belonging to complex
I, demonstrating that complex I components are more sus-
ceptible to the loss of HSP60 than the other complex
components. These selective effects on complex I compo-
nents may reflect specificity for interaction with HSP60, or
may reflect overall greater protein flux within complex I
components. Complex I is the largest and first enzyme of
the ETC, which is composed of 45 subunits and is essential
for cellular energy production, providing about 40% of the
proton motive force required for ATP synthesis [52].
Perturbed mitochondrial protein homeostasis in mutant
mice first led to increased expression of cardiac fetal genes
including ANF and βMHC 6 weeks post tamoxifen injec-
tion, suggesting that cardiac remodeling program was acti-
vated in mutant hearts even though UPRmt, mitochondrial
dysfunction, and abnormalities in cardiac morphology and
function were not observed in mutant hearts at this stage.
Subsequently, UPRmt was observed at 9 weeks post
tamoxifen injection, indicating that mutant mitochondria
were not able to degrade unfolded proteins, which started to
accumulate, and was accompanied with impaired complex I
and complex III activity, reduced mitochondrial membrane
potential, increased mitochondrial ROS production, and the
emergence of reduced cardiac systolic function in mutant
hearts. Later on, expression of LONP1 and HTRA2 was
increased in mutant hearts, likely as a compensatory
mechanism but still could not prevent mutant hearts from
developing chamber dilation and heart failure in the end.
Interestingly, downregulation of mitochondrial proteins in
HSP60CKO hearts 6 weeks post tamoxifen injection was not
accompanied by reduced mRNA levels, suggesting that
deletion of HSP60 does not affect transcription of these
genes. Furthermore, mitochondrial import and degradation
assays suggested that mitochondrial protein import was
largely normal in mutant mitochondria, which was also
consistent with the fact that we did not observe apparent
changes in expression of the Translocases of Inner Mito-
chondrial Membrane (TIMMs) or the Translocases of Outer
Mitochondrial Membrane (TOMMs) between control and
mutant mitochondria in our proteomic data. We also did not
observe any increases in expression of LONP1, CLPP, and
HTRA2 in mutant mitochondria at the same stage. Our
results further suggested that LONP1 may be the major
protease responsible for protein degradation in mitochondria
after HSP60 deletion, since addition of MG132, a LONP1
protease inhibitor [45, 46], rescued protein degradation in
cell preparations as well as in mitochondrial preparations.
Taken together, our study demonstrated that HSP60 is
required for maintaining normal cardiac morphology and
function. Loss of HSP60 in adult cardiomyocytes altered
mitochondrial protein homeostasis, impaired mitochondrial
function, and eventually resulted in dilated cardiomyopathy
and heart failure.
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